NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cellectar Biosciences, Inc. (CLRB) Stock Analysis

Cellectar Biosciences, Inc. (CLRB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CLRB

$1.28

+$0.05 (+4.07%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLRB with… →

CLRB Key Statistics

As of Oct 21, 2026
Trading
Open
$1.25
Previous Close
$1.23
Day's Range
1.23–1.33
52-Week Range
1.34–5.07
Volume
134.85K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.58
Valuation
Market Cap
$13.14M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.46
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$21.79M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.45M
1-Year Return
−69.60%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
64.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CLRB closed at $1.28, −69.60% over 1 year.

Cellectar Biosciences, Inc. (CLRB) has a market capitalization of $13.14M.

In fiscal 2025, CLRB reported revenue of $0.00.

CLRB Stock Return by Calendar Year

Cellectar Biosciences, Inc. (CLRB) 10-year return: what $10,000 became

1 year
$10,000 $3,040
−69.60%
5 years
$10,000 $46
−99.54%
10 years
$10,000 $2
−99.98%

If you had invested $10,000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, at the close on October 21, 2016, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −57.14% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−56.61%
2025−67.22%
2024−89.17%
2023+61.99%
2022−74.09%
2021−68.27%
2020−7.56%
2019+45.16%
2018−88.69%
2017+12.30%
2016 (partial year)−54.14%

As of October 21, 2026.

CLRB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$21.79M—
2024$0.00−$44.58M—
2023$0.00−$42.77M—
2022$0.00−$31.79M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$22.98M−$21.79M—
2024$0.00—−$51.78M−$44.58M—
2023$0.00—−$38.96M−$42.77M—
2022$0.00—−$28.81M−$31.79M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cellectar Biosciences, Inc. (CLRB) at $13.14M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 11.

The 52-week range on file runs from $1.34 to $5.07. The most recent close on file for CLRB is $1.28, dated October 21, 2026. That is +$0.05 (+4.07%) against the previous close.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $21.79M. Trailing earnings per share are −3.46.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.58. Daily returns over the trailing 10 years annualize to a volatility of 88.86%. The trailing one-year total return is −69.60%. Across 10 years the annualized return works out at −57.14%.

Growth & Income

No dividend is on file for CLRB.

So far in 2026 the total return is −56.61%. The strongest complete calendar year on file is 2023 at +61.99%; the weakest is 2024 at −89.17%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Cellectar Biosciences, Inc. (CLRB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cellectar Biosciences, Inc. CLRB $13.14M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cellectar Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Visit website →